Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1

Elevated apoC-III levels predict increased cardiovascular risk when present on LDL and HDL particles. We developed novel high-throughput chemiluminescent ELISAs that capture apoB, lipoprotein (a) [Lp(a)], and apoA-I in plasma and then detect apoC-III on these individual lipoproteins as apoCIII-apoB,...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xiaohong Yang, Sang-Rok Lee, Yun-Seok Choi, Veronica J. Alexander, Andres Digenio, Qingqing Yang, Yury I. Miller, Joseph L. Witztum, Sotirios Tsimikas
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2016-04-01
coleção:	Journal of Lipid Research
Assuntos:	hypertriglyceridemia triglycerides remnant lipoproteins antisense oligonucleotides cardiovascular disease familial chylomicronemia syndrome
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S0022227520354250
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!